Using risperidone for Alzheimer's dementia-associated psychosis
| Autor: | Anna Senseney, Karleen M McNeal, Renee P. Meyer, Karen Lukacs, Jacob Mintzer |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Psychosis
medicine.medical_specialty Population MEDLINE Alzheimer Disease Medicine Dementia Humans Pharmacology (medical) Psychiatry education Aged Pharmacology Aged 80 and over education.field_of_study Risperidone business.industry Aggression Incidence (epidemiology) General Medicine medicine.disease Psychotic Disorders medicine.symptom business Psychotropic Agent medicine.drug Antipsychotic Agents |
| Zdroj: | Expert opinion on pharmacotherapy. 9(14) |
| ISSN: | 1744-7666 |
| Popis: | Background: Alzheimer's dementia (AD) occurs in 6 – 8% of persons older than 65 years. The prevalence increases to 30% among those 85 years or older. Among AD patients, the incidence of psychosis is 30 – 50%. Safe and appropriate use of psychotropic agents is a relevant clinical concern for this population. Objective: This review addresses risks and potential benefits when risperidone is used for treating AD-associated psychosis. Methods: Through literature review and clinical experience, the authors discuss the clinical efficacy, safety, and regulatory issues concerning risperidone treatment for this group of patients. Conclusion: Despite concerns about safety, risperidone remains a popular therapeutic choice for AD patients with psychosis. Subsets of these patients with more severe agitation and aggression may experience greater behavioral benefit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|